• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient

tetano

Editor, Senior Moderator
Nat Commun


. 2023 Apr 10;14(1):1999.
doi: 10.1038/s41467-023-37591-w.
Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient


Lena Jaki[SUP] #[/SUP][SUP] 1 [/SUP], Sebastian Weigang[SUP] #[/SUP][SUP] 1 [/SUP], Lisa Kern[SUP] #[/SUP][SUP] 1 [/SUP], Stefanie Kramme[SUP] 2 [/SUP], Antoni G Wrobel[SUP] 3 [/SUP], Andrea B Grawitz[SUP] 4 [/SUP], Philipp Nawrath[SUP] 3 [/SUP], Stephen R Martin[SUP] 3 [/SUP], Theo Dähne[SUP] 1 [/SUP], Julius Beer[SUP] 1 [/SUP], Miriam Disch[SUP] 1 [/SUP], Philipp Kolb[SUP] 1 [/SUP], Lisa Gutbrod[SUP] 1 [/SUP], Sandra Reuter[SUP] 2 [/SUP], Klaus Warnatz[SUP] 5 6 [/SUP], Martin Schwemmle[SUP] 1 [/SUP], Steven J Gamblin[SUP] 3 [/SUP], Elke Neumann-Haefelin[SUP] 7 [/SUP], Daniel Schnepf[SUP] 1 [/SUP], Thomas Welte[SUP] 7 8 [/SUP], Georg Kochs[SUP] 1 [/SUP], Daniela Huzly[SUP] 1 [/SUP], Marcus Panning[SUP] 9 [/SUP], Jonas Fuchs[SUP] 10 [/SUP]



Affiliations

Abstract

Monoclonal antibodies (mAbs) directed against the spike of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are effective therapeutic options to combat infections in high-risk patients. Here, we report the adaptation of SARS-CoV-2 to the mAb cocktail REGN-COV in a kidney transplant patient with hypogammaglobulinemia. Following mAb treatment, the patient did not clear the infection. During viral persistence, SARS-CoV-2 acquired three novel spike mutations. Neutralization and mouse protection analyses demonstrate a complete viral escape from REGN-COV at the expense of ACE-2 binding. Final clearance of the virus occurred upon reduction of the immunosuppressive regimen and total IgG substitution. Serology suggests that the development of highly neutralizing IgM rather than IgG substitution aids clearance. Our findings emphasise that selection pressure by mAbs on SARS-CoV-2 can lead to development of escape variants in immunocompromised patients. Thus, modification of immunosuppressive therapy, if possible, might be preferable to control and clearance of the viral infection.
 
Back
Top Bottom